About Activiomics

Activiomics is a privately owned spin-out company from the Barts Cancer Institute.

It has developed innovative technologies that utilise mass spectrometry to interrogate and interpret the activity of cellular signalling pathways, generating high value information for the pharmaceutical and biotechnology industry.

Its novel TIQUAS platform enables the label free quantification of phosphopeptides for biomarker discovery and drug profiling. Unlike other phosphoproteomics techniques, TIQUAS can comprehensively profile and cross-compare phosphopeptides, ensuring accurate and reproducible data.

TIQUAS - Our Research and Technologies

About Activiomics

Contact us for more information